BenevolentAI
ben for atopic dermatitis atopic dermatitis is the most common chronic in skin disease characterized by intensely itchy red and swollen skin affects of children and up to of adults approximately of all cases present with mild moderate disease severity prevalence is rising with market value in forecast to exceed billion by ben is expected to treat atopic dermatitis by inhibiting itch signaling and blocking nerve sensitization in addition to inhibiting mediated dermal in using our molecular design we were able to design a inhibitor equipotent against the receptors atopic dermatitis treatment paradigm mild moderate severe ben will target mild moderate and severe patients addressing unmet need as a steroid sparing alternative and in more severe patients undergoing treatment with that require add on treatment i | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
March 2023
Slide
16 of 38
Similar slides by BenevolentAI
See diffirences between slides (animation)
Investor Conference
January 2023
topical best in class inhibitor to relieve in and rapidly resolve itch in patients with ben atopic dermatitis topical best in class inhibitor to relieve in and rapidly resolve itch in patients with | BenevolentAI
Investor Conference
November 2022
ben atopic dermatitis atopic dermatitis is the most common chronic in skin disease characterized by intensely itchy red and swollen skin affects of children and up to of adults approximately of all cases present with mild moderate disease severity prevalence is rising with market value in forecast to exceed billion skin in and chronic pruritus associated with atopic dermatitis negatively impact quality of life and psychosocial well being clear unmet need in mild to moderate patient segment for treatment addressing itch and in without side effects of steroids ben topical best in class inhibitor to relieve in and rapidly resolve itch in patients with ben is a inhibitor targeting and receptors the receptors were as part of an effort to mediators of both itch and in in using our molecular design we were able to design a inhibitor equipotent against the receptors ben is expected to treat atopic dermatitis by inhibiting itch signaling and blocking nerve sensitization in addition to inhibiting and mediated dermal in ben will target mild moderate and severe atopic dermatitis patients addressing unmet need in the treatment of mild to moderate atopic dermatitis as a steroid sparing alternative and in more severe patients undergoing treatment with that require add on treatment | BenevolentAI
Investor Presentation
October 2022
ben atopic dermatitis atopic dermatitis is the most common chronic in skin disease characterized by intensely itchy red and swollen skin affects of children and up to of adults approximately of all cases present with mild moderate disease severity prevalence is rising with market value in forecast to exceed billion skin in and chronic pruritus associated with atopic dermatitis negatively impact quality of life and psychosocial well being clear unmet need in mild to moderate patient segment for treatment addressing itch and in without side effects of steroids ben topical best in class inhibitor to relieve in and rapidly resolve itch in patients with ben is a inhibitor targeting and receptors the receptors were as part of an effort to mediators of both itch and in in using our molecular design we were able to design a inhibitor equipotent against the receptors ben is expected to treat atopic dermatitis by inhibiting itch signaling and blocking nerve sensitization in addition to inhibiting and mediated dermal in ben will target mild moderate and severe atopic dermatitis patients addressing unmet need in the treatment of mild to moderate atopic dermatitis as a steroid sparing alternative and in more severe patients undergoing treatment with that require add on treatment | BenevolentAI
Investor Presentation
June 2022
ben atopic dermatitis | BenevolentAI
Related slides by other companies
Ocuphire Pharma
Investor Presentation
August 2023
progression based on severity | Ocuphire Pharma
Kymera
Investor Presentation
December 2023
degrading best approach to block driven inflammation degrader advantage | Kymera
Direct Biologics
SPAC
October 2022
initial focus on moderate to severe induced by covid | Direct Biologics
Kymera
Investor Day
December 2021
mad reduced to near in the skin | Kymera
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Investor Conference
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io